Due to the site upgrade, your MY ACCOUNT logins will need to be updated. Please access Forgot Your Password to make this change. If you do not have an account, click here.

Once a day capsule offers real joint relief

Jun 09, 2015

A new, gold-standard, state of the art, randomized, double-blind, placebo-controlled clinical study that included 186 subjects with arthritic knees shows that UC-II reduced pain and stiffness and improved quality of life. The study lasted for 180 days.

UC-II® is collagen with undenatured type II collagen, an FDA-notified and published new dietary ingredient (NDI). It is derived from chicken sternum cartilage. UC-II® supports joint comfort, flexibility and mobility. UC-II is a FDA-notified and published new dietary ingredient. UC-II is supported by four human clinical studies, a number of studies of canines and horses, and is backed by numerous patents. In other studies just 40 mg of UC-II (in a once a day capsule) has been shown to increase joint comfort, flexibility and mobility. UC-II® provided statistically significant reduction in WOMAC scores compared to placebo in increasing joint function.

The primary endpoint of this study was defined as the change in overall WOMAC score by day 180 versus placebo. Secondary endpoints encompassed reductions in Lequesne Functional Index (LFI), Visual Analog Scale (VAS) for pain and the WOMAC subscales for pain, stiffness and physical function. The WOMAC score (Western Ontario and McMaster Universities Arthritis Index) is a widely used, proprietary set of standardized questionnaires used by health professionals to evaluate the condition of patients with osteoarthritis of the knee and hip, including pain, stiffness, and physical functioning of the joints. The WOMAC has also been used to assess back pain, rheumatoid arthritis, juvenile rheumatoid arthritis, Systemic Lupus and fibromyalgia. It was developed at Western Ontario and McMaster Universities in 1982.

Driving the change in overall WOMAC score for the UC-II group in this study were statistically significant reductions in the WOMAC pain, stiffness and physical function subscales. The UC-II group also demonstrated a significant reduction in total LFI and mean VAS scores compared to placebo.

Interestingly in the same study some of the patients were treated separately with glucosamine hydrochloride + chondroitin sulfate and UC-II strongly outperformed their effects. The findings of this latest clinical study were presented at the Scripps 12th Annual Natural Supplements Conference in San Diego, CA.

Note: The WOMAC measures five items for pain (score range 0–20), two for stiffness (score range 0–8), and 17 for functional limitation (score range 0–68). Physical functioning questions cover everyday activities such as climbing stairs, standing up from a sitting position, standing, bending, walking, getting in and out of a car, shopping, putting on or taking off socks, lying in bed, getting in or out of a bath, sitting, and heavy and light household duties.